MedPath

Implementation of pharmacokinetic (PK)-guided dosing of DDAVP and VWF-containing concentrates in von Willebrand disease and low VWF

Recruiting
Conditions
Von Willebrand disease, pharmacokinetics, treatment, bleeding, surgery
Registration Number
NL-OMON20178
Lead Sponsor
Erasmus University Medical Center - Sophia Children's Hospital, University Medical Center Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
123
Inclusion Criteria

No minimum or maximum age at inclusion date;

-Hemorrhagic symptoms or a family history of von Willebrand disease or low VWF with historically lowest levels of VWF:Ag and/or VWF:Act and/or VWF:Cb <0.60 IU/ml and/or FVIII <0.40 IU/ml (only in type 2N);

Exclusion Criteria

-Any other known hemostatic abnormalities;

-Acquired VWD;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
Ā© Copyright 2025. All Rights Reserved by MedPath